THE global rollout of Covid-19 vaccines has brought on a slew of new logistical challenges for vaccine manufacturers and logistics providers. While the capacity to meet the transport needs is adequate for now, it will not be enough as more players enter the Covid-19 vaccine manufacturing space, experts say. One of the three major challenges for vaccine makers is to get the vaccines out as quickly as possible, says Christina Yi, chief operating officer at US company Covaxx, a unit of United Biomedical Inc. “We cannot compromise on the safety and efficacy of our drugs. As such, manufacturers like Covaxx will take on additional business risks and costs that would not typically be economically viable in other circumstances such as moving forward with manufacturing multiple formulations on a large scale while waiting for the clinical trial results to determine the dosage amount,” she says during a panel discussion at the recent Covid-19 Vaccine Summit on Global Access and Distribution — Makers and Movers 2021.